CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer

Published:2024-07-17 Issue: Volume: Page:
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Sato Takumi,Oshi Masanori,Huang Jing Li,Chida Kohei,Roy Arya Mariam,Endo Itaru,Takabe Kazuaki

Funder

Roswell Park Comprehensive Cancer Center

National Institutes of Health

U.S. Department of Defense

Defense Health Agency

Rotary club

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10549-024-07434-3.pdf

Reference78 articles.

1. Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauss A, Blaudszun AR, Yevsa T, Fricke S, Kossatz-Boehlert U (2020) cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol 11:1280. https://doi.org/10.3389/fimmu.2020.01280

2. Butti R, Gunasekaran VP, Kumar TVS, Banerjee P, Kundu GC (2019) Breast cancer stem cells: biology and therapeutic implications. Int J Biochem Cell Biol 107:38–52. https://doi.org/10.1016/j.biocel.2018.12.001

3. Han J, Won M, Kim JH, Jung E, Min K, Jangili P, Kim JS (2020) Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. Chem Soc Rev 49(22):7856–7878. https://doi.org/10.1039/d0cs00379d

4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 100(7):3983–3988. https://doi.org/10.1073/pnas.0530291100

5. Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH (2012) CD44(+)/CD24(−/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43(3):364–373. https://doi.org/10.1016/j.humpath.2011.05.005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3